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ABSTRACT
Purpose: To determine prevalence of trachoma after interventions in 15 local government areas
(LGAs) of Kebbi, Sokoto and Zamfara States, Nigeria.
Methods: A population-based impact survey was conducted in each LGA using Global Trachoma
Mapping Project (GTMP) protocols. In each LGA, 25 villages were selected, except in Arewa LGA,
where we selected 25 villages from each of four subunits to obtain finer-resolution prevalence
information. Villages were selected with probability proportional to size. In each village, 25 households
were enrolled and all consenting residents aged ≥1 year were examined by GTMP-certified graders for
trachomatous inflammation—follicular (TF) and trachomatous trichiasis (TT). Information on sources of
household water and types of sanitation facilities used was collected through questioning and direct
observation.
Results: The number of households enrolled per LGA ranged from 623 (Kware and Tangaza) to 2488
(Arewa). There have been marked reductions in the prevalence of TF and TT since baseline surveys
were conducted in all 15 LGAs. Eight of the 15 LGAs have attained TF prevalences <5% in children,
while 10 LGAs have attained TT prevalences <0.2% in persons aged ≥15 years. Between 49% and 96%
of households had access to water for hygiene purposes within 1 km of the household, while only
10–59% had access to improved sanitation facilities.
Conclusion: Progress towards elimination of trachoma has been made in these 15 LGAs. Collaboration
with water and sanitation agencies and community-based trichiasis surgery are still needed in order to
eliminate trachoma by the year 2020.
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Introduction
For the elimination of trachoma as a public health problem,
the World Health Organization (WHO) recommends
implementation of the SAFE strategy (Surgery for tracho-
matous trichiasis (TT); Antibiotics to clear ocular
Chlamydia trachomatis infection; Facial cleanliness and
Environmental improvement to reduce C. trachomatis
transmission).1,2 The district-level elimination targets set
by WHO are a prevalence of trachomatous inflammation
—follicular (TF) of <5% in children aged 1–9 years, and a
prevalence of TT unknown to the health system of <0.2%
in persons aged ≥15 years.3 Experimental4,5 and
operational6,7 data suggest that the SAFE strategy works.
Countries are now scaling up or are already fully
implementing SAFE at scale,8,9 in an effort to achieve
elimination by the year 2020. The decision to continue
or discontinue elements of the SAFE strategy depends on
data from impact surveys, which are carried out after
specified periods of programme implementation.10–12
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In Nigeria, State governments partner with non-gov-
ernmental organisations to deploy trachoma elimination
activities at the district (local government area, LGA)
level. As elsewhere, the duration of intervention varies
between LGAs, depending on prevalence estimates of TF
and TT. In Kebbi, Sokoto and Zamfara States of north-
western Nigeria, trachoma programmes were gradually
rolled out from 2003. Baseline surveys were undertaken.
Local systems and capacities were developed to deliver
community-based trichiasis surgery, with operations per-
formed by trained ophthalmic nurses. Tetracycline eye
ointment and azithromycin were distributed, facial clean-
liness was promoted, and interventions launched to
improve access to water and sanitation.
To assess the collective impact of these interventions
in reducing the prevalence of disease towards elimina-
tion targets, we carried out impact surveys in the LGAs
of Kebbi, Sokoto and Zamfara States. The systems and
processes of the Global Trachoma Mapping Project13
(GTMP) were used. This paper reports the results of
those surveys, comparing the prevalence estimates
obtained with those generated at baseline.
Methods
Setting
Baseline population-based prevalence surveys for tra-
choma were conducted in 2004 in six LGAs of
Kebbi,14 six LGAs of Sokoto [unpublished data],
and six LGAs of Zamfara15 (Table 1). In 2006, six
further baseline surveys were conducted in Sokoto
State [unpublished data]. In 2011 and 2012, baseline
surveys were conducted in 25 LGAs of Sokoto and
Kebbi.16 In total, baseline surveys were conducted in
49 LGAs of Kebbi, Sokoto and Zamfara during the
period 2004–2012. Based on LGA-level prevalence
estimates of TF in children aged 1–9 years, 20
LGAs required 3 years of azithromycin mass drug
administration (MDA, TF prevalence 10–29.9%) and
7 other LGAs required 5 years of azithromycin MDA
(TF prevalence ≥30.0%), together with appropriate F
& E interventions. The remaining 22 LGAs had TF
prevalence estimates <10% and (according to then-
current WHO guidance12) did not qualify for dis-
trict-wide antibiotic MDA. Based on the prevalence
of trichiasis in persons aged ≥15 years, 40 LGAs
surveyed required community-based trichiasis sur-
gery to reach the trichiasis elimination threshold.
The decision was made to implement various aspects
of the SAFE strategy in 49 LGAs found to have
trachoma of public health significance (27 LGAs
with TF prevalence ≥10% and 40 LGAs with trichia-
sis prevalence ≥0.2%, of which 22 LGAs required
public-health-level trichiasis interventions [S], 9
LGAs required A, F and E, and 18 LGAs required
S, A, F and E). Health ministries in the three states
and relevant LGA offices partnered with the non-
governmental organisation Sightsavers to intervene
against trachoma.
Interventions commenced in 2003 with provision of
trichiasis surgery in six LGAs (including Arewa,
Argungu and Augie) of Kebbi, five LGAs (including
Goronyo, Illela, Isa and Rabah) of Sokoto and four
LGAs (including Birnin Magaji, Shinkafi and Zurmi)
of Zamfara. By the end of 2016, in the 15 LGAs under
review here, a total of 19,860 trichiasis surgeries had
been carried out (Table 1).
MDA of antibiotics commenced in 2004, using oral
azithromycin (Zithromax®, Pfizer, New York, NY,
USA) and/or 1% tetracycline eye ointment, each of
which was purchased on the open market. Funding
Table 1. Results of 15 selected baseline trachoma prevalence surveys conducted from 2004 to 2006, and consequent public health-
level actions, Kebbi, Sokoto and Zamfara States, Nigeria14,15,unpublished data.
State Local government area Year of baseline survey
Trichiasis prevalence
(≥15 years old, %)a Action (S)
TF prevalence
(1–9 years old, %)a Action (A, F, E)
Kebbi Arewa 2004 1.0 2390 13.6 3 years MDA, BCC
Argungu 2004 1.8 2415 16.3 3 years MDA, BCC
Augie 2004 0.9 1675 21.3 3 years MDA, BCC
Sokoto Binji 2006 2.1 413 29 3 years MDA, BCC
Gada 2004 3.1 1632 29.1 3 years MDA, BCC
Goronyo 2004 5.9 1290 26.8 3 years MDA, BCC
Gwadabawa 2006 4.0 927 49 5 years MDA, BCC
Illela 2004 3.1 1309 29.7 3 years MDA, BCC
Isa 2004 2.9 2163 13.5 3 years MDA, BCC
Kware 2006 5.6 666 43 5 years MDA, BCC
Rabah 2004 2.8 1339 21.4 3 years MDA, BCC
Tangaza 2004 2.7 1431 21.4 3 years MDA, BCC
Zamfara Birnin Magaji 2004 1.4 696 32.1 5 years MDA, BCC
Shinkafi 2004 1.2 803 17.9 3 years MDA, BCC
Zurmi 2004 1.1 711 22.7 3 years MDA, BCC
aUnadjusted.
A = antibiotics; BCC = behaviour change communication; F = facial cleanliness; E = environmental improvement; MDA = mass drug administration;
S = surgery; TF = trachomatous inflammation—follicular; TT = trachomatous trichiasis.
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limitations meant that quantities of antibiotics available
prior to 2010 were very limited, and as a consequence,
MDA was somewhat patchy and irregular. Donated
azithromycin (Zithromax®, Pfizer, supplied through
the International Trachoma Initiative9) became avail-
able in 2010 in Arewa (Kebbi), Gwadabawa (Sokoto)
and Birnin Magaji (Zamfara) and was expanded in
2011 to include two further LGAs in Kebbi and 14
further LGAs in Sokoto (Figure 1).
The facial cleanliness and environmental
improvement aspects of the SAFE strategy were
principally implemented through health education
and community sensitisation. Front-line heath
workers (government employees) provided basic
health education alongside other primary health
care duties at community health centres on a daily
basis. Community drug distributors displayed and
discussed posters about transmission, prevention
and treatment of trachoma during community
meetings and MDA events, with the aim of
encouraging safer hygiene practices and facial
cleanliness. Trachoma-endemic communities were
also provided with sanitation hardware (e.g., wheel-
barrows, shovels) to be used during monthly gen-
eral sanitation exercises for ensuring that faeces was
disposed of in ways that kept it away from human
contact. Community members were encouraged to
build toilets. Trained ophthalmic nurses also carried
out community mobilisation and health education
about trachoma during MDA and trichiasis surgery
Figure 1. Number of rounds of antibiotic mass drug administration (MDA) for trachoma, Kebbi, Sokoto and Zamfara States, Nigeria,
2010–2013.
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campaign activities, and encouraged, through
inspection, the use of sanitation facilities.
Impact survey rationale and design
Beginning in 2014, in each of the 15 LGAs (Figure 2), we
conducted cross-sectional population-based prevalence
surveys of persons aged ≥1 year, selected using multi-
stage cluster random sampling. These LGAs had not
necessarily completed the WHO-recommended num-
bers of MDA rounds indicated by their baseline TF
prevalence,12 but given the chequered history of inter-
vention and the long time period elapsed since the pre-
vious round of surveys, re-focussing the programme by
undertaking fresh estimates was felt to be a good idea.
We determined the required sample size for each
LGA based on the requirements to estimate a TF pre-
valence around the elimination threshold, using the
single-population proportion-for-precision formula:
n = 1.2 × (design effect) × p(1 − p)/(2 × d/
((1.96 × 2)2)). We used the following assumptions11,17:
expected TF prevalence in 1–9-year-olds (p) = 4%,
required absolute precision (d) = 2%, risk of α
error = 5% and design effect = 2.65. The calculated
minimal sample size was 978 children.
In each LGA (with the exception of Arewa), we
selected 25 clusters (villages) from a list of all villages in
the LGA, using a probability-proportional-to-village-size
methodology.12 We then segmented each selected village
(using pre-existing administrative units of approximately
equal size) and selected one of the units at random, by
Figure 2. Local government areas for trachoma impact surveys, Kebbi, Sokoto and Zamfara States, Nigeria, 2014–2016.
106 C. MPYET ET AL.
drawing lots. From the selected administrative unit, 25
households were selected using the random walk
method.18–23 Based on there being a mean of two children
aged 1–9 years per household, this was expected to allow
recruitment from a resident population of 1250 1–9-year-
olds in each LGA, which would allow for partial non-
response. In Arewa, we subdivided the LGA into four
subunits and selected 25 clusters from each, in order to
investigate how much additional information sub-dis-
trict-level surveys would provide in this environment at
the impact survey stage; thus a total of 100 clusters were
selected in Arewa. All residents aged ≥1 year, living in
selected households, were invited to participate.
Pre-survey field team training, certification and data
collection techniques followed standard GTMP
protocols.17 We used version 3 of the GTMP training
system.24
Ethics
Protocols were approved by the Ethics Committees of the
Ministries of Health of Kebbi and Sokoto States, the
National Health Research Ethics Committee of Nigeria
(NHREC/01/01/2007) and the London School of Hygiene
& Tropical Medicine (6319 and 8355), while Zamfara
State Ministry of Health gave permission for the survey
in the absence of a State Ethics Committee. After field
teams explained the examination protocol to each adult in
a language they understood, verbal consent for enrolment
and examination was obtained. (Most survey participants
could neither read nor write.) Heads of households gave
consent for the participation of minors, while adults gave
consent for their own participation. Consent was docu-
mented in an Open Data Kit-based Android smartphone
application (LINKS).25 Individuals with active trachoma
were given two tubes of 1% tetracycline eye ointment and
instructed on its use; persons with trichiasis were referred
for lid surgery at the nearest facility at which certified
trichiasis surgeons could be accessed. Examiners cleaned
their hands with an alcohol-based skin cleaning agent
after examination of each participant.
Data collection and definitions
We used the WHO simplified grading scheme to grade
trachoma.26 We recorded the presence or absence of TF,
trachomatous inflammation—intense, and trichiasis, on
the basis of the assessments of GTMP-certified trachoma
graders, one of whom examined each subject using ×2.5
magnifying loupes. In any eye with trichiasis, the grader
noted the presence or otherwise of trachomatous con-
junctival scarring.27 For the purposes of this paper, we
defined TT as the presence of trichiasis plus
trachomatous conjunctival scarring (or the grader find-
ing the upper eyelid impossible to evert) in the same eye.
GPS coordinates for each household were recorded, and
data on household-level access to water and sanitation
were collected through interviews and inspection (where
relevant) of household sanitation facilities. Sanitation
facilities were categorised as improved or unimproved,
as per the WHO/UNICEF Joint Monitoring Program
(JMP) for Water Supply and Sanitation definitions
used for monitoring progress towards the Millennium
Development Goals.28 Water sources referred to those
used for washing purposes, and not specifically for
drinking. Types of water sources were categorised as
improved and unimproved as per the JMP definitions.28
A household was defined as a compound head together
with all individuals normally resident in the compound
and eating from the same pot.
Data analysis
Data cleaning was undertaken by an objective (non-
programme-linked) data manager (RW). Data analysis
was performed using R (R Foundation for Statistical
Computing, Vienna, Austria) and Structured Query
Language. We controlled for age and gender of those
examined, and the total number of people examined
per cluster, using algorithms applied across all consti-
tuent projects of the GTMP.18–23,29–49 For TF, the pro-
portion of children aged 1–9 years who had that sign in
each cluster was adjusted for age in 1-year age bands.
For trichiasis and TT, the proportion of adults aged
≥15 years who had that sign in each cluster was
adjusted for age and gender in 5-year age bands.
Arithmetic means of the adjusted cluster-level propor-
tions gave the LGA prevalence for each sign.
Confidence intervals were generated by bootstrapping,
with replacement, the adjusted cluster-level propor-
tions, over 10,000 iterations.
Results
Surveys were conducted between 2014 and 2016. The
number of households enrolled per LGA ranged from
623 (Kware and Tangaza) to 2488 (Arewa). The num-
ber of children aged 1–9 years examined exceeded the
sample size estimate in every LGA except Kware, where
921 children (94% of the target) were examined. At
least as many persons aged ≥15 years as children aged
1–9 years were included in most LGAs – a reflection of
local demographics rather than refusal to participate,
which was rare (Table 2).
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Prevalence of trachoma
Prevalence estimates for TT in ≥15-year-olds and TF in
1–9-year-olds years old are shown in Table 3. Following
a 2015 impact survey (using the same methodologies
described above) in which the TF prevalence in 1–9-
year-olds years old was estimated to be 5.4%, Birnin
Magaji was given one further round of azithromycin
MDA, in 2016. An impact survey was conducted
8 months later; the TT and TF prevalence estimates
reported in Table 3 (and the data provided in Tables 2
and 5) are those generated in the second impact survey,
which followed a total of four rounds of azithromy-
cin MDA.
Marked reductions compared to baseline estimates, in
both the TT and TF indices, were noted in all 15 LGAs.
In the various sub-districts in Arewa, the prevalence of
TF in 1–9-year-olds ranged from 2.2% to 5.7%, while the
prevalence of TT in persons ≥15-year-olds ranged from
0.5% to 1.1% (Table 4).
If the trichiasis prevalence at baseline is compared to
the all-trichiasis prevalence at impact survey (ignoring
the presence or absence of trachomatous conjunctival
scarring), prevalence reductions from baseline to
impact are still noted (Table 5).
Access to water and sanitation
Across LGAs, access to a water source within 1 km of
households ranged from 49% to 96%, while access to an
improved water source ranged from 2% (Tangaza) to
79% (Birnin Magaji). Across all LGAs surveyed, access
to improved sanitation facilities was generally low, with
Birnin Magaji (59%) having the highest levels of access
(Table 6).
Discussion
In the LGAs for which we report trachoma impact
survey data here, there has been implementation of
some or all aspects of the SAFE strategy to varying
extents. Eight of the 15 LGAs (Arewa, Argungu,
Gwadabawa, Kware, Rabah, Birnin Magaji, Shinkafi
and Zurmi) have now attained the elimination target
for TF (<5% prevalence in 1–9-year-olds) and so enter
the 2-year surveillance phase.50 Implementation of azi-
thromycin MDA, even though irregular, combined with
education on the need for personal and environmental
hygiene, likely contributed to declines in TF prevalence.
Reduced TF prevalence is associated with a reduction
in the reservoir of ocular C. trachomatis, so this is
expected to be accompanied by decreased community
transmission intensity51 and, ultimately, a fall in the
incidence of TT.52
We are, however, unable to confidently credit
apparent falls in TF prevalence (Table 3) to imple-
mentation of the A, F and E components of the SAFE
strategy. We cannot even say with certainty that pre-
valence estimates at impact survey were significantly
lower than at baseline: scrutiny of the baseline survey
methodologies and data could not be undertaken
because the original datasets (and for some, even sur-
vey reports) could not be located, despite intensive
search. Baseline surveys conducted in these LGAs
used methodologies that almost certainly diverged in
important ways from the standards that were set up
some years later by the GTMP, including the fact that
the graders were not internationally standardised.
Furthermore, the present study was not a randomised
trial, but a series of post-intervention surveys, and
intervention delivery was intermittent, incomplete
and hard to quantify for each of the A, F and E
Table 2. Enumeration and examination characteristics of sampled individuals in 15 local government areas, impact surveys for
trachoma, Kebbi, Sokoto and Zamfara States, Nigeria, 2014–2016.
State
Local government
area
Households
surveyed
Persons
enumerated
Persons
examined, n (%)
Persons
absent
Persons refusing
examination
Total
1-9-year-
olds
≥15-year-
olds
1-9-year-
olds
≥15-year-
olds
1-9-year-
olds
≥15-year-
olds
1-9-year-
olds
≥15-year-
olds
Kebbi Argungu 765 4620 1754 2304 1651 (94) 1880 (82) 52 362 51 62
Augie 745 4388 1892 2057 1853 (98) 1861 (90) 22 179 17 16
Arewa 2488 13,606 5642 6733 5283 (94) 5672 (84) 190 895 169 166
Sokoto Gada 625 3385 1462 1589 1375 (94) 1294 (81) 39 146 47 148
Gwadabawa 726 3538 1458 1790 1370 (94) 1272 (71) 44 397 44 121
Kware 623 2698 956 1511 921 (96) 1388 (92) 7 110 28 13
Binji 625 3147 1275 1543 1246 (98) 1359 (88) 11 90 18 94
Goronyo 624 3694 1655 1622 1537 (93) 1239 (76) 72 175 46 208
Illela 624 3189 1300 1578 1255 (97) 1340 (85) 19 136 26 102
Isa 624 3598 1449 1690 1374 (95) 1314 (78) 43 213 32 162
Rabah 626 3368 1374 1598 1288 (94) 1205 (75) 50 184 36 208
Tangaza 623 3210 1300 1539 1241 (95) 1318 (86) 20 126 39 95
Zamfara Birnin Magajia 624 3701 1547 1814 1400 (90) 1537 (85) 88 233 59 44
Shinkafi 897 4285 1799 2120 1772 (98) 1828 (86) 12 221 15 71
Zurmi 895 5092 1927 2646 1792 (93) 2259 (85) 74 377 61 10
aSecond impact survey (2016).
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components. Though our survey methodology is con-
sidered best-in-class,53 we acknowledge residual weak-
nesses, including the use of random walk to select
households in Nigeria; reliance on self-report of access
to water and use of sanitation; exclusive focus in
questions about sanitation use on where household
adults defecate (ignoring sites of disposal of children’s
faeces); suboptimal recruitment (Table 2); and rela-
tively low sample sizes of adults.
Notwithstanding these limitations, our data reveal a
need to improve access to water and sanitation in these
LGAs. From the perspective of sustaining progress
against active trachoma, if water and sanitation54 and
behaviour change efforts55 do in fact help to reduce C.
trachomatis transmission, as many believe,56,57 there is
a particular imperative to undertake these activities in
the LGAs that have entered the surveillance phase on
the pathway towards elimination. In these populations,
Table 4. Prevalence of trachomatous inflammation—follicular (TF) and trachomatous trichiasis (TT), impact surveys, four sub-districts
of Arewa local government area, Kebbi State, Nigeria, 2014.
1-9-year-olds ≥15-year-olds
Sub-
district
Number of
households
sampled
Residents
enumerated
Residents
examined
Absent Refused TF prevalencea
(95% CI)
Residents
enumerated
Residents
examined
Absent Refused TT
prevalenceb
(95% CI)
1 595 1406 1271 48 87 5.1 (2.6–8.2) 1645 1438 183 22 1.1 (0.6–1.6)
2 599 1266 1202 27 37 4.1 (2.2–5.9) 1564 1326 191 46 1.0 (0.5–1.5)
3 648 1450 1365 68 16 2.2 (1.2–3.4) 1686 1408 262 16 0.6 (0.1–1.4)
4 646 1520 1445 47 28 5.7 (3.6–8.4) 1838 1500 259 79 0.5 (0.1–1.1)
aAdjusted for age in 1-year age bands.
bAdjusted for gender and age in 5-year age bands.
CI = confidence interval.
Table 5. Number of individuals with trichiasis, number of individuals with trichiasis + trachomatous conjunctival scarring (a
combination referred to here as trachomatous trichiasis, TT: see text) and prevalence of each of these things, impact surveys, 15
local government areas (LGAs) of Kebbi, Sokoto and Zamfara States, Nigeria, 2014–2016.
State LGA Number of ≥15-year-olds
with trichiasis
Trichiasis prevalence in ≥15-year-olds, %
(95% confidence interval)
Number of ≥15-year-
olds with TT
TT prevalence in ≥15-year-olds,
% (95% confidence interval)
Kebbi Argungu 13 0.53 (0.11–1.23) 3 0.05 (0.00–0.14)
Augie 17 0.49 (0.19–0.86) 9 0.26 (0.07–0.48)
Arewa 17 0.77 (0.52–1.09) 9 0.77 (0.51–1.10)
Sokoto Gada 8 0.99 (0.35–1.79) 3 0.1 (0.0–0.3)
Gwadabawa 16 0.82 (0,45–1.28) 10 0.03 (0.00–0.08)
Kware 8 0.26 (0.11–0.42) 8 0.3 (0.1–0.4)
Binji 22 1.83 (0.87–3.22) 8 0.4 (0.0–0.9)
Goronyo 13 0.70 (0.16–1.64) 1 0.03 (0.0–0.1)
Illela 16 0.68 (0.27–1.23) 2 0.04 (0.0–0.09)
Isa 9 0.36 (0.11–0.75) 2 0.04 (0.0–0.12)
Rabah 4 0.20 (0.03–0.48) 0 0
Tangaza 8 0.22 (0.05–0.48) 4 0.1 (0.0–0.28)
Zamfara Birnin Magaji 10 0.30 (013–0.51) 7 0.22(0.07–0.43)
Shinkafi 4 0.09 (0.01–0.19) 1 0.01 (0.00–0.04)
Zurmi 9 0.22 (0.06–0.42) 6 0.18 (0.03–0.38)
Table 6. Household access to water and improved sanitation facilities, 15 local government areas of Kebbi, Sokoto and Zamfara
States, Nigeria, 2014–2016.
State Local government
area
Access to a water source for washing within 1 km of the
household, %
Access to an improved water
source, %
Access to an improved sanitation
facility, %
Kebbi Argungu 96 72 42
Augie 88 33 12
Arewa 82 53 10
Sokoto Gada 54 33 17
Gwadabawa 62 17 16
Kware 71 28 24
Binji 90 7 11
Goronyo 74 30 29
Illela 81 8 20
Isa 85 44 34
Rabah 65 21 28
Tangaza 89 2 22
Zamfara Birnin Magajia 89 79 59
Shinkafi 67 58 25
Zurmi 49 53 19
aSecond impact survey (2016).
110 C. MPYET ET AL.
antibiotics will no longer be used to suppress the pre-
valence of infection, and keeping transmission intensity
low presumably depends on how successful F and E
have been. While >80% of households we sampled in
Arewa and Birnin Magaji had access to washing water
within 1 km of the residence, the other four LGAs in
which TF was <5% fell short of this mark. Of particular
concern in all LGAs is the very low access to improved
sanitation facilities, which may presage high muscid fly
densities and a greater chance of transmission of resi-
dual infection.58–61 In rural areas of Nigeria as a whole,
in the interval between 2000 and 2015, access to
improved sanitation reportedly decreased from 35% to
27% – a trend that, if continuing, requires urgent cor-
rection – while access to improved drinking water
sources increased from 36% to 62%.62
Although Arewa as a whole achieved the TF elim-
ination prevalence target, two of its sub-districts had TF
prevalences above that mark, estimated in fully fledged
independent surveys with more-than-adequate sample
sizes (Table 4). TF prevalences, however, were not sig-
nificantly different between the sub-districts. This
observation, though limited in scope, probably supports
the recent revision50 to WHO guidance on impact
surveys, in which previous recommendations63 to
frame impact surveys at sub-district level were changed
in favour of districts being the standard evaluation unit
at baseline, impact and surveillance phases of the pro-
gramme. We will, however, keep a close watch for
recrudescence of disease in the communities of Arewa.
Six surveyed LGAs (Augie, Gada, Binji, Goronyo, Isa
and Tangaza) require one round of azithromycin MDA
before impact surveys are repeated. During this period,
education on personal and environmental hygiene must
be ongoing. However, for education to be accepted and
implemented by communities, access to water and sani-
tation needs to be improved: all these LGAs had poor
household access to improved sanitation, and two of
them (Gada and Goronyo) also had <80% household
access to washing water within 1 km of the household.
One LGA (Illela) had a TF prevalence indicating a need
for three further rounds of azithromycin MDA together
with F and E.
The estimated TT prevalence was lower at impact
survey than at baseline survey in all LGAs. In Arewa,
the TT prevalence in sub-district 1 in 2014 (1.1, 95% CI
0.6–1.6) was, at face value, higher than the whole-LGA
trichiasis prevalence in 2004 (1.0, 95% CI 0.1–1.9),
despite more than double the estimated 2004 backlog
of Arewa trichiasis patients having been managed in the
intervening period (Tables 1 and 3). This result should
be more realistically interpreted in the light of the
imprecision of each estimate, but can also be taken as
a cautionary note against comparing prevalence esti-
mates generated at different administrative levels at
different times. Looking solely at LGA-level data,
there is also a lesson here about the continuing inci-
dence of TT even as TF prevalence falls, and the pitfalls
inherent in using surgical output data to predict the
success or otherwise of meeting the TT elimination
threshold prevalence.27
Ten LGAs recorded TT prevalences of <0.2% in
≥15-year-olds, the elimination threshold. In these
LGAs, there may be a reduced need for community-
based TT surgery, but structures to identify and treat
individuals who develop TT should be maintained.3
Robust follow-up mechanisms should also be contin-
ued, in order to detect post-surgical recurrence in
those previously operated, and to ensure patients
who elected for epilation over surgery but eventually
want more formal intervention are able to access it.
In LGAs with TT prevalence estimates ≥0.2%, pro-
gress (shown by reductions in trichiasis prevalence,
Tables 3 and 5) should also be celebrated, with an
eye to encouraging local teams to redouble their
efforts towards achieving elimination targets. Health
ministries will review the number, distribution, and
motivation of surgeons, and the extent to which they
are adequately equipped with the materials necessary
to do their jobs.
Much progress has been made towards the elimination
of trachoma in Kebbi, Sokoto and Zamfara States. While
some LGAs still require antibiotic MDA, greater emphasis
needs to be placed on collaboration with agencies involved
in water and sanitation to improve access to these services.
In addition, community-based trichiasis surgery needs to
be reinforced in four LGAs to finish the task of elimina-
tion of trachoma as a public health problem.
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